Trial Profile
An open label, two-period, single-sequence study of Dabigatran and Brincidofovir assessing inhibitor of P-Glycoprotein (P-gp) in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2016
Price :
$35
*
At a glance
- Drugs Brincidofovir (Primary) ; Dabigatran etexilate (Primary)
- Indications Adenovirus infections; Cytomegalovirus infections
- Focus Pharmacokinetics
- 21 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics